Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The differential association of conjugated equine estrogen and esterified estrogen with activated protein C resistance in postmenopausal women.

Journal of thrombosis and haemostasis : JTH - 1 Aug 2006

Smith N L, Heckbert S R, Doggen C J, Lemaitre R N, Reiner A P, Lumley T, Meijers J C M, Psaty B M, Rosendaal F R

Abstract excerpt

OBJECTIVES: Clinical trials have demonstrated that oral conjugated equine estrogen (CEE) therapy with or without medroxyprogesterone (MPA) increases venous thrombotic risk but this safety issue has not been investigated for other oral estrogens. Based on observational study findings that esterified estrogen (EE) was not associated with venous thrombotic risk whereas CEE was, we hypothesized that CEE users would...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Activated Protein C Resistance
Share to Administration, Oral

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Estrogen Replacement Therapy

Share to Hemostasis

Share to Horses

Share to Postmenopause

Share to Progestins

Share to Venous Thrombosis

Source

Identifiers

PMID: 16879211
DOI: 10.1111/j.1538-7836.2006.02045.x

Genes

APC

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The differential association of conjugated equine estrogen and esterified estrogen with activated protein C resistance in postmenopausal women.PMID 16879211Read ↗

HORMONE EXPOSURE AND VENOUS THROMBOEMBOLISM IN COMMERCIALLY-INSURED WOMEN 50 TO 64 YEARS OF AGESemantic proximity Read ↗

Estrogen receptor alpha polymorphism and venous thromboembolism in male and female: data from the EDITH study.Semantic proximity Read ↗

Venous thromboembolic disease in users of low-estrogen combined estrogen-progestin oral contraceptives.Semantic proximity Read ↗

Prothrombotic mutations, hormone therapy, and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration.Semantic proximity Read ↗

Hormone replacement therapy and acquired resistance to activated protein C: results of a randomized, double-blind, placebo-controlled trial.Semantic proximity Read ↗

Association between estrogen receptor alpha and beta gene polymorphisms and deep vein thrombosis.Semantic proximity Read ↗

Sensitivity to activated protein C during the menstrual cycle in women with and without factor VLeiden.Semantic proximity Read ↗

Effect of NFE2L2 genetic polymorphism on the association between oral estrogen therapy and the risk of venous thromboembolism in postmenopausal women.Semantic proximity Read ↗

Exogenous estrogen may exacerbate thrombophilia, impair bone healing and contribute to development of chronic facial pain.Semantic proximity Read ↗

Tamoxifen-associated venous thrombosis and activated protein C resistance due to factor V Leiden.Semantic proximity Read ↗

Normalized activated protein C ratio itself not associated with increased risk of venous thromboembolism.Semantic proximity Read ↗

Synergism between oral estrogen therapy and cytochrome P450 3A5*1 allele on the risk of venous thromboembolism among postmenopausal women.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.